









GALDERMA AESTHETICS:
WORKING IN **HARMONY**
WITH **EACH** INDIVIDUAL

Often the natural look that makes us who we are is achieved with a combination of treatments¹

Galderma offers a collection of complementary aesthetic treatments to give patients a relaxed, refined, refreshed and renewed look.

	Relax	REFINE	Refresh	Renew
				
				
TREATMENT AREAS	Glabellar and lateral canthal lines	Face	Face, neck, décolletage and hands	Face and body
ACTIVE INGREDIENT	Botulinum toxin type A	Stabilised hyaluronic acid (HA)	Stabilised hyaluronic acid (HA)	Poly-L-lactic acid (PLLA)
PURPOSE	Relax the muscles involved in the formation of dynamic wrinkles in the glabellar lines and lateral canthal lines	Provide lift, shape and enhance contours, fill lines and wrinkles, create volume	Improve skin quality and radiance	Renew skins volume by stimulating natural collagen production
DURATION	Up to 5 months ^{2,3*}	Up to 24 months with one retreatment ^{4,5}	Up to 12 months ^{6†}	Up to 25 months ^{7,8‡}

*In glabellar lines. †Skin elasticity, hands. ‡In nasolabial folds.

PBS information: 500U vial, 300U vial: Section 100. Authority required (STREAMLINED). Refer to the PBS schedule for full information. This product is not listed for glabellar lines or lateral canthal lines. 125U vial: This product is not PBS listed.

Please review Product Information before prescribing.
The Product Information can be accessed at www.ebs.tga.gov.au/dysport
or Ph: 1800 800 765

Dysport®: Clostridium botulinum type A toxin-haemagglutinin complex (125, 300, 500 IPSEN UNITS/vial). **Indications:** Symptomatic treatment of focal spasticity affecting the upper and lower limbs in adults; spasmodic torticollis in adults; symptomatic treatment of lower limb focal spasticity in children aged 2 years of age and older; blepharospasm in adults; hemifacial spasm in adults; moderate to severe glabellar lines and / or lateral canthal lines (crow's feet) in adults. **Contraindications:** Hypersensitivity to ingredients; myasthenia gravis or Eaton-Lambert (myasthenic) syndrome; infection at proposed injection site. **Precautions:** The units of Dysport are not interchangeable with other preparations of botulinum type A toxin. Use lowest effective dose and do not exceed recommended dosages and frequencies of administration; adverse effects from toxin distribution to sites remote from the site of administration have been reported (excessive muscle weakness). Use with extreme caution in patients with breathing and swallowing difficulties, sub-clinical or clinical evidence of neuromuscular transmission defects (including drug-induced), and prolonged bleeding times. Use with extreme caution in paediatric patients who have significant neurologic debility, dysphagia, or have a recent history of aspiration pneumonia or lung disease. Antibody formation to botulinum toxin may occur rarely; contains small amount of human albumin so the risk of transmission of viral infection cannot be excluded; ensure ready availability of adrenaline injection in cases of anaphylactic reaction; use in pregnancy only if benefit justifies risk. **Drug Interactions:** Any drugs which interfere with neuromuscular transmission (e.g. muscle relaxants, aminoglycoside antibiotics). **Adverse Effects:** common to very common depending on indication: asthenia, fatigue, influenza-like illness, injection site pain/bruising/swelling/erythema/pruritis/rash/paraesthesia/haematoma; dysphagia, falls; headache, dizziness, facial paresis, blurred vision, visual acuity reduced, dysphonia, dyspnoea, dry mouth, muscle weakness, neck pain, musculoskeletal pain, myalgia, pain in extremity, musculoskeletal stiffness; urinary incontinence, gait disturbance; ptosis, diplopia, dry eyes, lacrimation increased, eyelid oedema; asthenopia, muscle twitching; periorbital haematoma. **Dose:** The units of Dysport are not interchangeable with other preparations of botulinum type A toxin. Recommended minimum interval between treatments is 12 weeks. Focal spasticity of upper limb: up to 1000 units. Focal spasticity of lower limb: up to 1500 units. Spasmodic torticollis: 250-1000 units. Focal spasticity of lower limb in children aged 2 years of age and older: 15-30 units/kg bodyweight, up to a maximum of 1000 units. Blepharospasm & hemifacial spasm: 40-120 units/eye. Glabellar lines: 50 units. Lateral Canthal lines: 30 units per side. **Administration:** Intramuscular injection for all indications except blepharospasm / hemifacial spasm where it is injected subcutaneously. **Storage:** 2°C - 8°C.

References: 1. Carruthers A *et al. J Cosmet Laser Ther* 2007;9(suppl.1):6-10. 2. Dysport Approved Product Information. 3. Galderma. Data on file (MA-31936). 4. Andriopoulos B *et al.* Poster presented at AMWC 2019. 5. Data on file (MA-39364). 6. Gubanova E *et al. J Drugs Dermatol* 2015;14(3):288-98. 7. Narins RS *et al. J Am Acad Dermatol* 2010;62(3):448-462. 8. Brandt FS *et al. Aesthet Surg J* 2011;31(5):521-528.

Galderma Australia Pty Ltd, 13B Narabang Way, Belrose NSW 2085. Phone: 1800 144 944, Fax: +61 2 9986 1699, ABN 12 003 976 930. Dysport is distributed by Galderma Australia Pty Ltd for the glabellar lines and lateral canthal lines indication only. Sponsor: Ipsen Pty Ltd, Level 2, Building 4, Brandon Office Park, 540 Springvale Road, Glen Waverley, Victoria 3150 Australia.

Dysport® is a registered trademark of Ipsen Pty Ltd. Restylane and Galderma are trademarks of Galderma S.A.
A&C19-12-0969. AES0096. January 2020.

